South San Francisco, Ca Access Newswire February 25, 2026 CASI Pharmaceuticals, Inc. Nasdaq Casi , a clinical-stage biopharmaceutical company focused on developing Cid-103, a potential best-in-class, anti-CD38 monoclonal
Why Is CASI Pharmaceuticals, Inc. (CASI) Stock Down Today?
Updated Nov 22, 2026 5:31 AM ET ยท Prev Close $0.80
This stock is down 74% today โ a major single-session selloff. Confirm volume stabilization and key support defense before entering.
Session Regime & Catalyst Assessment
68% Signal ConvictionCASI Pharmaceuticals, Inc. Pulling Back 74.06% on 1.00x Relative Volume
CASI Pharmaceuticals, Inc. (CASI) is pulling back 74.06% (-$0.59) to $0.21 on 1.00x average session volume. Relative to benchmarks, CASI is lagging the S&P 500 by -70.42%. 14-day RSI stands at 18.4, keeping momentum in a oversold regime.
South San Francisco, Ca Access Newswire February 25, 2026 CASI Pharmaceuticals, Inc. Nasdaq Casi , a clinical-stage biopharmaceutical company focused on developing Cid-103, a potential best-in-class, anti-CD38 monoclonal
Price ($0.21) trades relative to 20-day SMA ($0.84) and 50-day SMA ($0.88).
Market & Sector Relative Strength
CASI lagging the S&P 500 by -70.42%Options Flow & Execution Desk
Recent CASI Catalyst Headlines
Verified WireCid-103 is a potential best-in-class, anti-CD38 monoclonal antibody binds to unique CD38 epitope AMR is a leading cause of kidney transplant loss with no approved treatments U.S. IND previously approved by FDA for Phase
Additional proof of concept data consistent and strengthen data set shared at Ash 2025 Management to host meetings at JP Morgan 44th Annual Healthcare Conference 2026 San Francisco, California Access Newswire January 12,
South San Francisco, California Access Newswire December 23, 2025 CASI Pharmaceuticals, Inc. Nasdaq Casi , a clinical-stage biopharmaceutical company focused on developing Cid-103, a potential best-in-class, anti-CD38 mo
1โ3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.21 (session support) for directional breakout confirmation.
Technical Regime (CASI)
BEARISH MA TRENDRetail & Crowd Sentiment
NeutralCASI Pharmaceuticals announced it will be delisted from Nasdaq due to failure to meet listing requirements. The Company intends to trade on the OTC market following delisting.
About CASI Pharmaceuticals, Inc.
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The Evomela injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include Cid-103, CNCT19, Evomela, Marqibo, โฆ
Get Instant CASI Catalyst Alerts
Receive an email alert when CASI triggers an unusual volume breakout, options sweep, or rating shift.
CASI Session & Catalyst FAQ
Why is CASI stock down today?
CASI Pharmaceuticals, Inc. (CASI) is pulling back 74.06% (-$0.59) to $0.21 on 1.00x average session volume. Relative to benchmarks, CASI is lagging the S&P 500 by -70.42%. 14-day RSI stands at 18.4, keeping momentum in a oversold regime.
Is CASI stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 1.00x relative volume (moderate participation). Our multi-factor model currently rates CASI as HOLD. Review full valuation, quality, and timing signals on the CASI Buy or Sell Decision Brief โ
What is CASI's intrinsic value and expected trading range?
At $0.21, CASI's modeled 1-to-3 session range is $0.20 โ $0.22, with a key inflection level at $0.21 (session support). Compare current price against multi-year cash flow projections in the CASI Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for CASI?
RSI at 18.4 indicates oversold conditions โ watch for mean-reversion support. CASI trades at $0.21 relative to its 20-day SMA ($0.84) and 50-day SMA ($0.88), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.